{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:59:37Z","timestamp":1793681977721,"version":"4.5.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016606","name":"Riley Children's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005300","name":"American Chemical Society","doi-asserted-by":"publisher","award":["16-192-31"],"award-info":[{"award-number":["16-192-31"]}],"id":[{"id":"10.13039\/100005300","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003341","name":"Sarcoma Foundation of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006733","name":"Indiana University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010249","name":"Indiana University School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014042","name":"US Department of Defense Peer Reviewed Cancer Research Program","doi-asserted-by":"publisher","award":["CA230160"],"award-info":[{"award-number":["CA230160"]}],"id":[{"id":"10.13039\/100014042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006975","name":"Indiana Clinical and Translational Sciences Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NIH NCI","doi-asserted-by":"publisher","award":["P30CA082709"],"award-info":[{"award-number":["P30CA082709"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.neo.2025.101266","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:28:47Z","timestamp":1768462127000},"page":"101266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Dual CDK4\/6\u2013PI3K\/mTOR inhibition reinforces cytostatic programs and tumor control in preclinical models of primary and metastatic osteosarcoma"],"prefix":"10.1016","volume":"72","author":[{"given":"Farinaz","family":"Barghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Reza","family":"Saadatzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika A.","family":"Dobrota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4871-8683","authenticated-orcid":false,"given":"Harlan E.","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rada","family":"Malko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryli","family":"Justice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niknam","family":"Riyahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadijeh","family":"Bijangi-Vishehsaraei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9115-5124","authenticated-orcid":false,"given":"Keiko","family":"Kreklau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7247-2372","authenticated-orcid":false,"given":"Lauren K.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6952-955X","authenticated-orcid":false,"given":"Jenna","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirzat","family":"Sulayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Trowbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Coy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia M.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony L.","family":"Sinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Just","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle W.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sandusky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Daniel","family":"Wurtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1022-1072","authenticated-orcid":false,"given":"Dana","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4578-899X","authenticated-orcid":false,"given":"Emily E.","family":"Seiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0921-983X","authenticated-orcid":false,"given":"Edward M.","family":"Greenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0049-0073","authenticated-orcid":false,"given":"Emma","family":"Doud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Mosley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7655-657X","authenticated-orcid":false,"given":"Steven P.","family":"Angus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1398-7217","authenticated-orcid":false,"given":"Michael J.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankita H.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6031-5707","authenticated-orcid":false,"given":"Karen E.","family":"Pollok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2025.101266_bib0001","first-page":"6228","article-title":"Progress in the chemotherapeutic treatment of osteosarcoma","volume":"16","author":"Zhang","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.neo.2025.101266_bib0002","article-title":"Bone Cancer, Version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Biermann","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.neo.2025.101266_bib0003","first-page":"14","article-title":"Precision medicine highlights dysregulation of the CDK4\/6 cell cycle regulatory pathway in pediatric, adolescents and young adult sarcomas","author":"Barghi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neo.2025.101266_bib0004","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bbadis.2018.02.004","article-title":"Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma","volume":"1864","author":"Zhou","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis. Dis."},{"key":"10.1016\/j.neo.2025.101266_bib0005","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1038\/sj.emboj.7600459","article-title":"E2Fs link the control of G1\/S and G2\/M transcription","volume":"23","author":"Zhu","year":"2004","journal-title":"EMBO J."},{"key":"10.1016\/j.neo.2025.101266_bib0006","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.21873\/anticanres.15115","article-title":"Combination of CDK4\/6 and mTOR inhibitors suppressed doxorubicin-resistant osteosarcoma in a patient-derived orthotopic xenograft mouse model: a translatable strategy for recalcitrant disease","volume":"41","author":"Oshiro","year":"2021","journal-title":"Anticancer Res."},{"key":"10.1016\/j.neo.2025.101266_bib0007","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer","volume":"76","author":"Herrera-Abreu","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2025.101266_bib0008","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","article-title":"Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy","volume":"3","author":"Li","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.neo.2025.101266_bib0009","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1535-7163.MCT-13-0639","article-title":"Picking the point of inhibition: a comparative review of PI3K\/AKT\/mTOR pathway inhibitors","volume":"13","author":"Dienstmann","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.neo.2025.101266_bib0010","article-title":"Voxtalisib and low intensity pulsed ultrasound combinatorial effect on glioblastoma multiforme cancer stem cells via PI3K\/AKT\/mTOR","volume":"239","author":"Tutak","year":"2022","journal-title":"Pathol. Res. Pr."},{"key":"10.1016\/j.neo.2025.101266_bib0011","article-title":"Potential biomarkers of resistance to CDK4\/6 inhibitors: a narrative review of preclinical and clinical studies","volume":"2","author":"Huang","year":"2020","journal-title":"Transl. Breast Cancer Res."},{"key":"10.1016\/j.neo.2025.101266_bib0012","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1023\/A:1006623001465","article-title":"A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies","volume":"17","author":"Jia","year":"1999","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.neo.2025.101266_bib0013","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1023\/A:1006767007547","article-title":"An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential","volume":"18","author":"Khanna","year":"2000","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.neo.2025.101266_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092426","article-title":"Systems biology approach identifies prognostic signatures of poor overall survival and guides the prioritization of novel BET-CHK1 combination therapy for osteosarcoma","volume":"12","author":"Pandya","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neo.2025.101266_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010259","article-title":"Integrative Multi-OMICs identifies therapeutic response biomarkers and confirms fidelity of clinically annotated, serially passaged patient-derived xenografts established from primary and metastatic pediatric and AYA solid tumors","volume":"15","author":"Pandya","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neo.2025.101266_bib0016","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1158\/1535-7163.MCT-15-0237","article-title":"Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model","volume":"14","author":"Tonsing-Carter","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.neo.2025.101266_bib0017","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10585-010-9324-1","article-title":"A sensitive polymerase chain reaction-based method for detection and quantification of metastasis in human xenograft mouse models","volume":"27","author":"Malek","year":"2010","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.neo.2025.101266_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252048","article-title":"Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK","volume":"16","author":"Chang","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.neo.2025.101266_bib0019","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/neuonc\/noy046","article-title":"EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma","volume":"20","author":"Angus","year":"2018","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.neo.2025.101266_bib0020","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/jnc.15226","article-title":"A multi-omic analysis of the dorsal striatum in an animal model of divergent genetic risk for alcohol use disorder","volume":"157","author":"Grecco","year":"2021","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neo.2025.101266_bib0021","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/19466315.2018.1437071","article-title":"Evaluation of drug combination effect using a Bliss independence dose-response surface model","volume":"10","author":"Liu","year":"2018","journal-title":"Stat. Biopharm. Res."},{"key":"10.1016\/j.neo.2025.101266_bib0022","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/cas.12932","article-title":"Phase I study of palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, in Japanese patients","volume":"107","author":"Tamura","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.neo.2025.101266_bib0023","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-13-2403","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K\/mTOR inhibitor in patients with advanced solid tumors","volume":"20","author":"Papadopoulos","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2025.101266_bib0024","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s43018-023-00667-z","article-title":"Additivity predicts the efficacy of most approved combination therapies for advanced cancer","volume":"4","author":"Hwangbo","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.neo.2025.101266_bib0025","doi-asserted-by":"crossref","DOI":"10.15761\/CRR.1000145","article-title":"Aberrant expression of p16(INK4a) in human cancers - a new biomarker?","volume":"2","author":"Inoue","year":"2018","journal-title":"Cancer Rep. Rev."},{"key":"10.1016\/j.neo.2025.101266_bib0026","doi-asserted-by":"crossref","first-page":"9232","DOI":"10.1128\/JVI.01072-15","article-title":"A screen for extracellular signal-regulated kinase-primed glycogen synthase kinase 3 substrates identifies the p53 inhibitor iASPP","volume":"89","author":"Woodard","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.neo.2025.101266_bib0027","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/s41388-019-1052-7","article-title":"VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway","volume":"39","author":"Zhangyuan","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2025.101266_bib0028","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1095\/biolreprod.109.076497","article-title":"Linker histones stimulate HSPA2 ATPase activity through NASP binding and inhibit CDC2\/Cyclin B1 complex formation during meiosis in the mouse","volume":"81","author":"Alekseev","year":"2009","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.neo.2025.101266_bib0029","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2694","article-title":"Signal integration by JNK and p38 MAPK pathways in cancer development","volume":"9","author":"Wagner","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.neo.2025.101266_bib0030","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1091\/mbc.e04-12-1087","article-title":"Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells","volume":"16","author":"Trisciuoglio","year":"2005","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.neo.2025.101266_bib0031","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/627254","article-title":"The genetics of osteosarcoma","volume":"2012","author":"Martin","year":"2012","journal-title":"Sarcoma"},{"key":"10.1016\/j.neo.2025.101266_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154902","article-title":"New emerging targets in osteosarcoma therapy: PTEN and PI3K\/akt crosstalk in carcinogenesis","volume":"251","author":"Sadrkhanloo","year":"2023","journal-title":"Pathol. - Res. Pract."},{"key":"10.1016\/j.neo.2025.101266_bib0033","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41392-023-01661-8","article-title":"Phase II trial of CDK4\/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4\/CDKN2A","volume":"8","author":"Martin-Broto","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.neo.2025.101266_bib0034","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.neo.2017.05.003","article-title":"Combined inhibition of CDK4\/6 and PI3K\/AKT\/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells","volume":"19","author":"Bonelli","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.neo.2025.101266_bib0035","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.21873\/anticanres.13565","article-title":"Sorafenib and Palbociclib combination regresses a cisplatinum-resistant osteosarcoma in a PDOX mouse model","volume":"39","author":"Higuchi","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.neo.2025.101266_bib0036","article-title":"Clinical utility of CDK4\/6 inhibitors in Sarcoma: successes and future challenges","volume":"6","author":"Hsu","year":"2022","journal-title":"JCo Precis. Oncol."},{"key":"10.1016\/j.neo.2025.101266_bib0037","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.4161\/cc.7.18.6733","article-title":"GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma","volume":"7","author":"Dal Col","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.neo.2025.101266_bib0038","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","article-title":"CDK4\/6 Inhibition in cancer: beyond cell cycle arrest","volume":"28","author":"Goel","year":"2018","journal-title":"Trends. Cell Biol."},{"key":"10.1016\/j.neo.2025.101266_bib0039","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41698-022-00311-6","article-title":"Co-targeting CDK2 and CDK4\/6 overcomes resistance to aromatase and CDK4\/6 inhibitors in ER+ breast cancer","volume":"6","author":"Al-Qasem","year":"2022","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.neo.2025.101266_bib0040","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1158\/1535-7163.MCT-17-0537","article-title":"Combined inhibition of mTOR and CDK4\/6 is required for optimal blockade of E2F function and long-term growth inhibition in estrogen receptor-positive breast cancer","volume":"17","author":"Michaloglou","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.neo.2025.101266_bib0041","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13046-020-01763-z","article-title":"Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma","volume":"39","author":"Xue","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.neo.2025.101266_bib0042","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.27539","article-title":"Combined inhibition of PIM and CDK4\/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells","volume":"11","author":"Litchfield","year":"2020","journal-title":"Oncotarget."},{"key":"10.1016\/j.neo.2025.101266_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12717\/DR.2016.20.1.001","article-title":"Blockage of autophagy rescues the dual PI3K\/mTOR inhibitor BEZ235-induced growth inhibition of colorectal cancer cells","volume":"20","author":"Oh","year":"2016","journal-title":"Dev. Reprod."},{"key":"10.1016\/j.neo.2025.101266_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106628","article-title":"Combination of palbociclib with navitoclax based-therapies enhances in vivo antitumoral activity in triple-negative breast cancer","volume":"187","author":"Estepa-Fern\u00e1ndez","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neo.2025.101266_bib0045","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.yexcr.2017.09.031","article-title":"Palbociclib-induced autophagy and senescence in gastric cancer cells","volume":"360","author":"Valenzuela","year":"2017","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.neo.2025.101266_bib0046","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1158\/1078-0432.CCR-17-3421","article-title":"A first-in-Human phase 1 study of LY3023414, an oral PI3K\/mTOR dual inhibitor, in patients with advanced cancer","volume":"24","author":"Bendell","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2025.101266_bib0047","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/pbc.25963","article-title":"Prevalence of metastasis at diagnosis of osteosarcoma: an international comparison","volume":"63","author":"Marko","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.neo.2025.101266_bib0048","doi-asserted-by":"crossref","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","article-title":"The PRIDE database at 20 years: 2025 update","volume":"53","author":"Perez-Riverol","year":"2025","journal-title":"Nucleic. Acids. Res."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625001459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625001459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:20:42Z","timestamp":1773966042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558625001459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":48,"alternative-id":["S1476558625001459"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2025.101266","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual CDK4\/6\u2013PI3K\/mTOR inhibition reinforces cytostatic programs and tumor control in preclinical models of primary and metastatic osteosarcoma","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2025.101266","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101266"}}